ESR1 and breast cancer: For instance, hypermethylation of ERα promoter leads to ERα deficiency, whereas treatment with DNA demethylating reagents plus inhibitors for histone deacetylases (HDACs) would restore ERα expression and tamoxifen (TAM) sensitivity in ERα-negative BC (ERα− BC) cells (11–13).